ImmunityBio, Inc.

IBRXNASDAQHealthcare● Active

$7.17

+$0.25(+3.61%)

Market Cap$7.5B

P/E Ratio—

52W High$12.43

52W Low$1.95

Avg Volume18.1M

Open$7.12

Beta0.10

Free Cash Flow Financials Revenue

ImmunityBio, Inc. (IBRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IBRX · free cash flow · updated Jun 9, 2026

Core FCF metrics

IBRX · FCF · TTM · margin & CAGR

Free cash flow was −$308.8M for FY2025 (fiscal year ending 2025-12-31), up 22.4% year-over-year The FCF margin was -272.6%.

FY2025 Free Cash Flow−$308.8M▲ +22.4% YoY

Trailing 12M (TTM)−$298.9Mtrailing 4 quarters sum

FCF Margin-272.6%−$308.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IBRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$304.9M(4M)−$308.8M▲ +22.4%-272.6%

FY2024−$391.2M(7M)−$398.1M▼ 0.2%—

FY2023−$366.8M(31M)−$397.3M▲ +4.4%—

FY2022−$337.5M(78M)−$415.7M▼ 35.0%—

FY2021−$274.4M(34M)−$308.0M▼ 77.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IBRX · P/FCF · FCF yield · FCF per share

ImmunityBio, Inc. (IBRX) reported negative free cash flow of −$0.31B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

IBRX · cash flow statement · operating / investing / financing

For FY2025, ImmunityBio, Inc. generated −$304.9M in operating cash flow and spent 4M in capital expenditures, yielding −$308.8M in free cash flow.

Operating Activities

−$304.9M

Cash from core business operations

2025-12-31

Investing Activities

−$149.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$400.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$304.9M) − |CapEx| (4M) = FCF (−$308.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IBRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ImmunityBio, Inc.YOU

IBRX

−$308.8M+22.4%-272.6%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ImmunityBio, Inc. (IBRX) reported free cash flow of −$308.8M for FY2025 (fiscal year ending 2025-12-31), up 22.4% year-over-year. The FCF margin was -272.6%.

ImmunityBio, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 13 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IBRX free cash flow · 8 questions

ImmunityBio, Inc. free cash flow was −$308.8M for FY2025, up 22.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$298.9M.

IBRX free cash flowIBRX FCFIBRX FCF 2025IBRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ImmunityBio, Inc. · ImmunityBio, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026